Transformation of the Ukrainian pharmaceutical market – new opportunities and potential Pharmaceutical Industry Review, September No 4 (97) 2023
pharmaceutical market, in particular, the growing demand for drugs to treat post-traumatic stress disorder, with further growth in the future of products for the treatment of chronic diseases and diseases of the elderly population. How has your company's product range changed since the beginning of the war? What trends do you observe?
The first task we faced was to restore our portfolio of drugs that we had before the start of the Great War. We had to bring back the medicines that patients need from the defective stock. Therefore, in 2023, we are focusing on this. So far, we have replanished most of the items from the defective stock.
Speaking about the strategic vision for the near future, we choose to work in a targeted manner with certain therapeutic areas. Currently,
28 BACK TO CONTENTS
our top priorities are cardiology, neurology and surgery portfolios. In these areas, we already have a certain reputation and effective drugs. For example, our thiocolchicoside, which I mentioned earlier and which we launched recently, in November 2022, in very difficult conditions, now has almost 12% of the market in packs. In cardiology, we focus on modern treatment trends and popular combinations. This is reflected in our cardiology portfolio. Our isosorbide dinitrate in spray form has only one analog on the Ukrainian market. We have the most complete line of products based on perindopril and valsartan, including triple combinations, which is very important for doctors to select the right dosage for the treatment of hypertension – from the onset of the disease to resistant hypertension. Therefore, we focus our attention on the development and
introduction of innovative medicines into our portfolio, launching medicines that have proven to be effective in other countries and are part of the global treatment standards, but have not yet become popular and widely available in Ukraine.
How did your company overcome the logistics crisis to export its drugs and import raw materials and equipment?
Yes, the supply chains have changed a lot and this has become another challenge. We have carefully analyzed all existing contracts and focused on only a few of the most reliable partners – global leaders in the supply of raw materials and packaging materials. Our experts have calculated all possible deviations and scenarios. Meeting exact delivery deadlines is essential in the manufacture of medicines, especially when it
www.promoboz.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
